ArticleBMC gastroenterology2025
Analysis of risk factors and correlation between the degree of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatohepatitis (MASH) is a chronic metabolic liver disease. This study sought to investigate risk factors and correlation between degree of hepatic steatosis and fibrosis in patients with MASH. MATERIALS AND
methodsTotal 175 MASH patients were divided into 240 ~ 264 dB/m group, 265 ~ 294 dB/m group and ≥ 295 dB/m group according to controlled attenuation parameters (CAP) to evaluate hepatic steatosis, < 7.3 kPa and ≥ 7.3 kPa groups according to liver stiffness value (LSM) to assess liver fibrosis. Multivariate logistic regression analysis analyzed influencing factors of hepatic steatosis and liver fibrosis. Correlation between hepatic steatosis and fibrosis and non-invasive prediction model for liver fibrosis was explored.
resultsCompared with 240-264dB/m group, body mass index (BMI), alanine aminotransferase (GPT), aspartate aminotransferase (GOT), uric acid (UA), and LSM levels increased in 265-294dB/m and ≥ 295dB/m group, which were higher in ≥ 295dB/m group (P < 0.05). Relative to < 7.3 kPa group, BMI, GPT, GOT, and CAP levels increased and neutrophil/lymphocyte (NLR) decreased in ≥ 7.3 kPa group (P < 0.001). BMI, GPT, UA and LSM were risk factors affecting hepatic steatosis; GOT and CAP were risk factors affecting liver fibrosis, while NLR was a protective factor (P < 0.05). There was a positive correlation (r = 0.572, P < 0.001) between LSM and degree of hepatic steatosis. The optimal cutoff value of established a non-invasive liver fibrosis predictive model was 0.492 with AUC of 0.819 (95% CI: 0.735-0.903). The internal validation by Bootstrap method showed good discrimination of the predictive model with the corrected AUC of 0.801.
conclusionsThere is a positive correlation between liver steatosis and fibrosis. Establishing non-invasive prediction model for liver fibrosis has a good predictive value for liver fibrosis in MASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.